Discovery Labs (DSCO) – Grafico e Operatività
Discovery Laboratories, Inc., incorporated in 1992, is a biotechnology company developing surfactant therapies to treat respiratory disorders and diseases. The Company’s KL4 technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for survival and normal respiratory function. In addition, its capillary aerosol-generating technology (capillary aerosolization technology) produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 surfactant to the lung. The Company is developing its products, Surfaxin(lucinactant), Surfaxin LS and Aerosurf, to address the respiratory conditions affecting neonatal populations. It has filed a New Drug Application (NDA) for its product based on its KL4 surfactant technology, Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The Company focuses on manufacturing three additional Surfaxin batches for the preclinical program.
Surfaxin LS, the Company’s lyophilized KL4 surfactant, is a dry powder formulation that is resuspended as a liquid prior to use. Aerosurf is its KL4 surfactant in aerosolized form, which it is developing using its capillary aerosolization technology, initially to treat premature infants at risk for RDS. In addition to its lead products, the Company is focusing on developing its KL4 surfactant technology into a product pipeline that will address a variety of debilitating respiratory conditions. During the year ended December 31, 2010, the Company initiated Phase 2a clinical trial concluded assessing the safety, tolerability and short-term effectiveness (via improvement in mucociliary clearance) of its aerosolized KL4 surfactant in patients with Cystic Fibrosis (CF). The Company is conducting research and preclinical development with its KL4 surfactant potentially to address Acute Lung Injury (ALI) and other diseases associated with inflammation of the lung, such as Asthma and Chronic Obstructive Pulmonary Disease (COPD). During 2010, the Company concluded a Phase 2 clinical trial of Surfaxin administered intratracheally as a liquid bolus in children with acute respiratory failure (ARF), a pediatric respiratory condition that is often caused by severe respiratory infections.
The Company competes with Chiesi Farmaceutici S.p.A., Cornerstone Therapeutics Inc., Abbott Nutritionals, Inc. and ONY, Inc.
Profile & Board — REUT-Fin.Data — YHOO Fin.Data — FINVIZ-Fin.Data — BARCH-Fin.Data — GOOG Fin.Data — ZACK Fin.Data — Y-Fin.Data
SEC — Owners — Insiders — Short-data — Options — Analysts — NewsByGOOG — NewsByDSCO & I.R. — Products
Sul grafico annuale & lineare a candele si notano due elementi decisamente interessanti (segni e non segnali):
-) nel 2012 (I trimestre) s’è al momento stoppata la progressione ribassista strutturale sulla company; difatti non ci sono stati rinnovati minimi mentre il massimo 2012 > 2011;
-) la colonna volumetrica del primo trimestre 2012 è quasi pari all’intero anno 2011; segno di abbandono in massa della company o segno di violenta accumulazione ???
Il presente post non ha valore per l’operatività stretta (frames brevi: settimanale o meno); al più, ha utilità di tipo strutturale, al fine di meglio comprendere l’evoluzione prezzi della company.